Pancreatic Cancer, Resected Clinical Trial
Official title:
A Phase I/II Trial of TG01 and Gemcitabine as Adjuvant Therapy for Treating Patients With Resected Adenocarcinoma of the Pancreas
| Verified date | May 2020 |
| Source | Targovax ASA |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of this study is to investigate the effect of TG01 and Granulocyte macrophage
colony stimulating factor (GM-CSF) when given in addition to gemcitabine (chemotherapy) and
- Understand any possible side effects of the additional use of TG01/GM-CSF with
gemcitabine
- Investigate whether TG01/GM-CSF when given with gemcitabine can produce an immune
response
- Investigate if the treatment can delay or reduce recurrence of the disease
| Status | Completed |
| Enrollment | 32 |
| Est. completion date | May 2019 |
| Est. primary completion date | May 2019 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 99 Years |
| Eligibility |
Inclusion Criteria: 1. Histologically or cytologically confirmed diagnosis of adenocarcinoma of the pancreas 2. Stage I or II disease (clinical stage T1-3, N0-1, M0 by AJCC staging criteria). 3. Successful surgical resection - Complete resection (R0) or with microscopic residual disease (R1) - Expected to receive gemcitabine monotherapy as adjuvant chemotherapy 4. Laboratory Values: - Absolute neutrophil count = 1.5 x 10^9/l - Platelets =100 x 10^9/l - Haemoglobin = 9 g/dl - Total bilirubin = 1.5 x UNL - Serum creatinine = 1.5 x UNL - Albumin = 2.5 g/dl - AST or ALT = 5 x UNL 5. 18 years of age or older. 6. ECOG performance status (PS) of 0-1. 7. Life expectancy of at least 6 months 8. Men and women of childbearing potential must be willing to use effective methods of contraception to prevent pregnancy 9. Provide written (signed) informed consent to participate in the trial prior to any trial specific screening procedures Exclusion Criteria: 1. Has received an investigational drug within 4 weeks prior to Trial drug administration 2. Has received previous therapy for pancreatic cancer including radiation or chemotherapy (except for the primary resection or primary neoadjuvant chemotherapy). 3. Is currently receiving any agent with a known effect on the immune system, unless at dose levels that are not immunosuppressive (e.g. Prednisone at 10 mg/day or less or as inhaled steroid at doses used for the treatment of asthma). 4. Has any other serious illnesses or medical conditions such as, but not limited to: - Any uncontrolled infection - Uncontrolled cardiac failure classification III or IV (NY Heart Association) - Uncontrolled systemic and gastro-intestinal inflammatory conditions - Bone marrow dysplasia - History of auto-immune disease - History of adverse reactions to vaccines 5. Known history of positive tests for HIV/AIDS, hepatitis B or C 6. Pregnant or lactating females or have no pregnancy test at baseline (postmenopausal women must have been amenorrhoeic for at least 12 months to be considered of non-childbearing potential). 7. Contraindication to gemcitabine treatment 8. Have had any other malignancies within last 3 years (except for adequately treated carcinoma of the cervix or basal or squamous cell skin cancer) 9. Known malignant brain lesion(s) 10. Are unlikely to start chemotherapy within 12 weeks of surgery (e.g. delayed wound healing, or infection, etc.) 11. Are not expected to complete 6 cycles of chemotherapy 12. Are planned to receive yellow fever or other live (attenuated) vaccines during the course of study |
| Country | Name | City | State |
|---|---|---|---|
| Norway | Oslo University Hospital HF the Norwegian Radium Hospital | Oslo | |
| Spain | Centro Integral Oncologico Clara Campal / Hospital HM Universitario Sanchinarro | Madrid | |
| United Kingdom | Queen Elizabeth University Hospital / Edgaston / | Birmingham | |
| United Kingdom | University of Liverpool / Molecular and Clinical Cancer Medicine | Liverpool | |
| United Kingdom | University of Manchester / The Christie NHS Foundation Trust | Manchester |
| Lead Sponsor | Collaborator |
|---|---|
| Targovax ASA |
Norway, Spain, United Kingdom,
Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug I, Søreide O, Eriksen JA, Møller M, Baksaas I, Lothe RA, Saeterdal I, Gaudernack G. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer. 2001 May 1;92(3):441-50. — View Citation
Wedén S, Klemp M, Gladhaug IP, Møller M, Eriksen JA, Gaudernack G, Buanes T. Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int J Cancer. 2011 Mar 1;128(5):1120-8. doi: 10.1002/ijc.25449. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Relationship Between (KRAS) Status and Clinical Efficacy | Relationship between KRAS status and recurrence | 2 years | |
| Primary | Patients' Safety During Study | Assess the safety (number and nature of Adverse events and laboratory data occurring during study (before, during and after chemotherapy is given) in subjects treated with the Pancreatic Cancer ASCI | 2 years | |
| Primary | Patients' Immune Response | Assess the Immune response (DTH responses and Proliferative T-cell responses) up to 2 years of treatment | During the 2 years of treatment | |
| Secondary | Clinical Efficacy | Efficacy exploring disease free survival and overall survival. | DFS was followed for up to 2 years and OS until last patient included had been in the study for 3 years. |